The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma

1. Howlader, N, Noone, A, Krapcho, M, et al. SEER cancer statistics review, 1975–2017. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/ (2020; accessed 13 February 2020).
Google Scholar2. Fonseca, R, Abouzaid, S, Bonafede, M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia 2017; 31: 1915–1921.
Google Scholar | Crossref | Medline3. Stewart, AK, Rajkumar, SV, Dimopoulos, MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142–152.
Google Scholar | Crossref | Medline | ISI4. Dimopoulos, MA, Lonial, S, White, D, et al. ELOQUENT-2 update: a phase 3, randomized, open-label study of elotuzumab in combination with lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma – 3-year safety and efficacy follow-up. Presented at the American Society of Hematology (ASH), Annual Meeting and Exposition, , Orlando, FL, USA.
Google Scholar5. Amgen . KYPROLIS® (carfilzomib) for injection, for intravenous use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202714s027lbl.pdf (2019, accessed 13 February 2020).
Google Scholar6. Dimopoulos, MA, Oriol, A, Nahi, H, et al. An open-label, randomised, phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX. Paper presented at the 21st Annual Congress of the European Hematology Association, , Copenhagen, Denmark. Abstract: LB2238.
Google Scholar7. San Miguel, J, Weisel, K, Moreau, P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 1055–1066.
Google Scholar8. Moreau, P, Masszi, T, Grzasko, N, et al. Ixazomib, an investigational oral Proteasome Inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): the phase 3 tourmaline-MM1 study (NCT01564537). Paper presented at the ASH: 57th Annual Meeting and Exposition, 2015, Orlando, FL, USA.
Google Scholar9. San-Miguel, JF, Hungria, VT, Yoon, S-S, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15: 1195–1206.
Google Scholar10. Food and Drug Administration . FDA approves new treatment for refractory multiple myeloma. US Department of Health and Human Services. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma (2019; accessed 13 February 2020).
Google Scholar11. US Food and Drug Administration . FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. Silver Spring, MD. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma (2020; accessed 14 September 2020).
Google Scholar12. Cook, R . Economic and clinical impact of multiple myeloma to managed care. J Manag Care Pharm 2008; 14 (7 Suppl.): 19–25.
Google Scholar | Crossref | Medline13. Schulman, KL, Kohles, J. Economic burden of metastatic bone disease in the US. Cancer 2007; 109: 2334–2342.
Google Scholar | Crossref | Medline14. Kenney, J . The rationale for comparing the costs of competing treatment options in oncology. Am Health Drug Benefits 2015; 8: 214.
Google Scholar15. Becker, GS, Philipson, TJ, Soares, RR. The quantity and quality of life and the evolution of world inequality. Am Econ Rev 2005; 95: 277–291.
Google Scholar | Crossref | Medline | ISI16. Yin, W, Penrod, JR, Maclean, R, et al. Value of survival gains in chronic myeloid leukemia. Am J Manag Care 2012; 18 (11 Suppl.): S257–S264.
Google Scholar17. MacEwan, JP, Yin, W, Kaura, S, et al. The value of survival gains in myelodysplastic syndromes. Am J Manag Care 2017; 23: e10–e15.
Google Scholar | Medline18. MacEwan, JP, Yin, W, Kaura, S, et al. The value of survival gains in pancreatic cancer from novel treatment regimens. J Manag Care Spec Pharm 2017; 23: 206–213.
Google Scholar | Crossref | Medline19. National Cancer Institute . ICD-O-3 SEER site/histology validation list. https://seer.cancer.gov/icd-o-3/ (2019; accessed 13 February 2020).
Google Scholar20. Biegelsen, Birchenough, Huang L, et al. US Multiple Myeloma Market– June 2018 Data. Medical Technology Biotechnology: Wells Fargo Securities, Equity Research, 2018.
Google Scholar21. Agency for Healthcare Research and Quality (AHRQ) . Medical Expenditure Panel Survey (MEPS). Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/research/data/meps/index.html (2015; accessed 13 February 2020).
Google Scholar22. US Food and Drug Administration . Drug Approval Package: Velcade (bortezomib). US Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21602_Velcade.cfm (2002, accessed 13 July 2020).
Google Scholar23. US Food and Drug Administration . Drug approval package: Revlimid (Lenalidomide). US Department of Health and Human Services. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021880s000_RevlimidTOC.cfm (2006; accessed 13 July 2020).
Google Scholar24. Becker, GS . A theory of the allocation of time. Econ J 1965; 75: 493–517.
Google Scholar | Crossref | ISI25. US Bureau of Labor Statistics . Databases, tables & calculators by subject. Washington, DC: US Department of Labor. https://data.bls.gov/PDQWeb/cu (2019, accessed 8 May 2019).
Google Scholar26. Dimopoulos, MA, San-Miguel, J, Belch, A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica 2018; 103: 2088–2096.
Google Scholar | Crossref | Medline27. Moreau, P, Mateos, M-V, Berenson, JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (ARROW): interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018; 19: 953–964.
Google Scholar | Crossref | Medline28. Lonial, S, Dimopoulos, M, Palumbo, A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621–631.
Google Scholar | Crossref | Medline | ISI29. Dimopoulos, MA, Moreau, P, Palumbo, A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27–38.
Google Scholar | Crossref | Medline | ISI30. Sood, N, Shih, T, Van Nuys, K, et al. The flow of money through the pharmaceutical distribution system. Washington, DC: Brookings Institution, 2017.
Google Scholar31. Celgene Corporation . US SEC form 10-K (annual report) 2011. http://www.sec.gov/Archives/edgar/data/816284/000104746912001293/a2207399z10-k.htm (2015; accessed 14 September 2020).
Google Scholar32. US Food and Drug Administration . Orange book: approved drug products with therapeutic equivalence evaluations, 36th ed. Rockville, MD: US Department of Health and Human Services. http://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm (2016; accessed 14 September 2020).
Google Scholar33. FORM 10-K [Internet] , Washington, DC: United States Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/14272/000001427216000288/bmy-20151231x10xk.htm (2015; accessed 14 September 2020).
Google Scholar34. Friedman, Y . DrugPatentWatch. https://www.drugpatentwatch.com/p/biologics/tradename/DARZALEX (2020; accessed 14 September 2020).
Google Scholar35. Conti, R, Berndt, E. Specialty drug prices and utilization after loss of US patent exclusivity, 2001-2007. Working Paper 20016. Cambridge, MA: National Bureau of Economic Research, 2014.
Google Scholar36. Basu, A, Jena, AB, Philipson, TJ. The impact of comparative effectiveness research on health and health care spending. J Health Econ 2011; 30: 695–706.
Google Scholar | Crossref | Medline37. Lakdawalla, DN, Sun, EC, Jena, AB, et al. An economic evaluation of the war on cancer. J Health Econ 2010; 29: 333–346.
Google Scholar | Crossref | Medline38. Lakdawalla, D, Shafrin, J, Lucarelli, C, et al. Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains. Health Aff (Millwood) 2015; 34: 555–561.
Google Scholar | Crossref | Medline39. Institute for Clinical and Economic Review . Treatment options for relapsed or refractory multiple myeloma: effectiveness,value,and value-based price benchmarks: final evidence report and meeting summary. Boston, MA: Midwest Comparative Effectiveness Public Advisory Council, 2016.
Google Scholar40. Jakubowiak, AJ, Campioni, M, Benedict, Á, et al. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ 2016; 19: 1061–1074.
Google Scholar | Crossref | Medline41. Zhang, T-T, Wang, S, Wan, N, et al. Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma. Clin Ther 2018; 40: 1122–1139.
Google Scholar | Crossref | Medline42. Aldy, J, Viscusi, W. Adjusting the value of a statistical life for age and cohort effects. Rev Econ Stat Rev Econ Stat 2008; 90: 573–581.
Google Scholar | Crossref | ISI43. Brown, RE, Stern, S, Dhanasiri, S, et al. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ 2013; 14: 507–514.
Google Scholar | Crossref | Medline44. Lakdawalla, DN, Shafrin, J, Hou, N, et al. Predicting real-world effectiveness of cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework. Value in Health 2017; 20: 866–875.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif